Background: Cytomegalovirus (CMV) infection exacerbates ulcerative colitis (UC) refractory to immunosuppressive therapies (IMT). However, the underlying UC remained active in some UC patients, despite the fact that CMV-DNA in colonic mucosa became negative after antiviral therapy. Therefore, new therapeutic strategies for UC patients concomitant with CMV infection in mucosa are required. Aims: The aim of this study was to evaluate the effect and safety of granulocyte-monocyte adsorption apheresis (GMA) in UC patients positive for CMV infection after antiviral therapy. Methods: From October 2003 to December 2008, 64 patients with UC refractory to IMT, including steroids and immunomodulators, were enrolled in this retrospective, observational, multicenter study, which was reviewed and approved by the Institutional Review Board of Kyoto University. CMV infection was investigated by 3 methods (histologic examination, CMV antigenemia, and polymerase chain reaction). We investigated the clinical outcomes of GMA and IMT after 2 weeks of treatment with ganciclovir. Results: Thirty-one (48.4%) of 64 patients with UC refractory to IMT were positive for CMV. Of the 31 patients, 4 (12.9%) underwent colectomy. Twenty-seven patients (87.1%) underwent antiviral therapy. Of those 27 patients, 7 achieved remission following antiviral therapy alone. Of the remaining 20 patients who did not achieve remission despite the disappearance of CMV-DNA, 11 and 9 patients were treated with additional GMA (GMA group) and IMT (IMT group), respectively. Of 11 patients (GMA group), 9 achieved remission and 2 underwent colectomy. Out of the remaining 9 patients (IMT group), 4 achieved remission and 5 underwent colectomy. CMV-DNA was not detected in 11 patients after GMA, but it was detected again in all 5 patients of the IMT group who underwent colectomy. The total colectomy rate in UC patients positive for CMV was 35.5% (11/31). In addition, colectomy-free survival in the CMV relapse (+) group was estimated to be 12.9% at 65 months, while that in the CMV relapse (–) group was estimated to be 100% at 60 months. Conclusion: The colectomy ratio tends to be high in refractory UC patients with recurrent CMV reactivation or infection. Therefore, GMA might be a safe and effective treatment for UC patients positive for CMV because it does not induce CMV reactivation.

Journal Section:
Original Paper
Keywords:
Ulcerative colitis, Cytomegalovirus, Granulocyte-monocyte adsorption apheresis, Ganciclovir
1.
Nakase H, Matsumura K, Yoshino T, et al: Systematic review: cytomegalovirus infection in inflammatory bowel disease. J Gastroenterol 2008;43:735–740.
[PubMed]
https://doi.org/10.1007%2Fs00535-008-2246-x
2.
Nakase H, Yoshino T, Ueno S, et al: Importance of early detection of cytomegalovirus infection in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007;13:364.
[PubMed]
https://doi.org/10.1002%2Fibd.20033
3.
Yoshino T, Nakase H, Ueno S, et al: Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis 2007;13:1516–1521.
[PubMed]
https://doi.org/10.1002%2Fibd.20253
4.
Kou T, Nakase H, Tamaki H, et al: Cytomegalovirus infection in patients with ulcerative colitis diagnosed by quantitative real-time PCR analysis. Dig Dis Sci 2006;51:1052–1055.
[PubMed]
https://doi.org/10.1007%2Fs10620-006-8006-y
5.
Domènech E, Roser V, Ojanguren I, et al: Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis 2008;14:1373–1379.
[PubMed]
https://doi.org/10.1002%2Fibd.20498
6.
Onyeagocha C, Hossain MS, Kumar A, et al: Latent cytomegalovirus infection exacerbates experimental colitis. Am J Pathol 2009;175:2034–2042.
[PubMed]
https://doi.org/10.2353%2Fajpath.2009.090471
7.
Shimoyama T, Sawada K, Hiwatashi N, et al: Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001;16:1–9.
[PubMed]
https://doi.org/10.1002%2Fjca.1000
8.
Simon Co, Seckert CK, Dreis D, et al: Role of tumor necrosis factor-α in murine cytomegalovirus transcriptional reactivation in latently infected lungs. J Virol 2005;79:326–340.
[PubMed]
https://doi.org/10.1128%2FJVI.79.1.326-340.2005
9.
Chan G, Bivins-Smith ER, Smith MS, et al: Transcriptome analysis reveals human cytomegalovirus reprograms monocyte differentiation toward an M1 macrophage. J Immunol 2008;181:698–711.
[PubMed]
10.
Matts SG: The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med 1961;30:393–407.
[PubMed]
11.
Cottone M, Pietrosi G, Martorana G, et al: Prevalence of cytomegalovirus infection in severe refractory ulcerative colitis and Crohn’s colitis. Am J Gastroenterol 2001;96:773–775.
[PubMed]
https://doi.org/10.1111%2Fj.1572-0241.2001.03620.x
12.
Papadakis KA, Tung JK, Binder SW, et al: Outcome of cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:2137–2142.
[PubMed]
https://doi.org/10.1111%2Fj.1572-0241.2001.03949.x
13.
Hommes DW, Sterringa G, van Deventer SJ, et al: The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis 2004;10:245–250.
[PubMed]
https://doi.org/10.1097%2F00054725-200405000-00011
14.
Nakase H, Yoshino T, Matsumura K, et al: Positive finding of colonic PCR for CMV DNA is not false positive but warning for treating patients with UC refractory to immunosuppressive therapies. Inflamm Bowel Dis (in press).
15.
Rubin RH: Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990;12(suppl 7):S754–S766.
[PubMed]
16.
Nakase H, Chiba T: TNF-α is an important pathogenic factor contributing to reactivation of cytomegalovirus in inflamed mucosa of colon in patients with ulcerative colitis: lesson from clinical experience. Inflamm Bowel Dis 2010;16:550–551.
[PubMed]
https://doi.org/10.1002%2Fibd.21080
17.
Criscuoli V, Mocciaro F, Orlando A, et al: Cytomegalovirus disappearance after treatment for refractory ulcerative colitis in two patients treated with infliximab and one patient with leukapheresis. Inflamm Bowel Dis 2009;15:810–811.
[PubMed]
https://doi.org/10.1002%2Fibd.20742
18.
D’Ovidio V, Vernia P, Gentile G, et al: Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNF-α therapy. J Clin Virol 2008;43:180–183.
[PubMed]
https://doi.org/10.1016%2Fj.jcv.2008.06.002
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.